OpenAI To Launch Web Browser In Challenge To Google’s Dominance
Artificial intelligence (A.I.) start-up OpenAI is reportedly planning to release an internet search engine in what’s being described as a direct challenge to Google parent company Alphabet (GOOGL).Privately held OpenAI is planning to release an A.I.-powered web browser of its own to challenge Google Chrome. The move by OpenAI comes after rival A.I. start-up Perplexity launched it’s A.I. internet search engine called Comet.OpenAI, which is best known as the company behind ChatGPT, reportedly plans to release its web browser in the coming weeks. Much like Perplexity’s Comet, OpenAI’s browser will use A.I. to rethink how users browse the internet.The browser may keep some user interactions inside ChatGPT instead of linking to external websites. The OpenAI browser may also integrate Operator, the company’s web-browsing A.I. agent, as a key feature that helps boost online search results.Executives at OpenAI have talked publicly about building a browser to compete with Google for years. Much like Perplexity, OpenAI wants to get direct access to user data and have the freedom to create user experiences that aren’t intermediated by the Google search engine.Competing web browsers are viewed by some Wall Street analysts as a major threat to Alphabet’s dominance in online search through its Google Chrome portal.GOOGL stock is down 7% this year and trading at $176.62 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


